Table 6.
Cox regression analysis for overall survival in newly diagnosed primary AML.
| Covariates | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Agea | 2.628 (1.824-3.786) | 0.000 | 2.495 (1.708-3.644) | 0.000 |
| Gender (male vs. female) | 1.050 (0.756-1.460) | 0.770 | ||
| WBCb | 0.980 (0.704-1.365) | 0.906 | ||
| Blasts in PBc | 1.291 (0.655-2.542) | 0.461 | ||
| Blasts in BMd | 0.812 (0.330-2.001) | 0.651 | ||
| Cytogeneticse | 1.508 (0.827-2.753) | 0.180 | ||
| Prognostic levelf | 1.761 (1.261-2.458) | 0.001 | 1.004 (0.694-1.451) | 0.984 |
| Bone marrow fibrosis | 0.000 | 0.000 | ||
| BMF-0 VS BMF-1 | 2.853 (1.850-4.400) | 0.000 | 2.556 (1.602-4.078) | 0.000 |
| BMF-0 VS BMF-2/3 | 2.053 (1.626-2.591) | 0.000 | 2.203 (1.661-2.924) | 0.000 |
| BMF-1 VS BMF-2/3 | 1.531 (1.029-2.278) | 0.036 | 1.577 (1.051-2.366) | 0.028 |
HR, hazard ratio; CI, confidence interval; aAge < 60 years old versus ≥ 60 years old; bWBC ≤10×109/L versus WBC >10×109/L; cBlasts in peripheral blood versus without blasts; dBlasts in bone marrow >20% versus = 20%; eLow risk versus intermediate and high risk; fLow and intermediate risk versus high risk; AML, acute myeloid leukemia.